Overture Life secures US$57m to automate IVF

Overture Life has raised US$20.6m, bringing its total funding to US$57m from leading industry investors, to support additional clinical research and product development designed to make IVF affordable to more people.

VF is currently inaccessible for many people, with inefficiencies driving up costs. Overture’s newest platform, DaVitri, addresses essential lab steps that historically rely on manual precision.

By standardising these procedures with precise timing and controlled cryoprotectant exposure, DaVitri has demonstrated improved oocyte survival rates in early clinical evaluations, potentially reducing repeated IVF cycles that can drain resources and emotional energy.

In addition, its streamlined, gentler freezing process helps clinics maintain consistent lab results, allowing embryologists to handle more cycles without compromising quality.

“This new funding allows us to accelerate our expansion of IVF capabilities and demonstrates the value of operating within a CLIA-licensed laboratory environment, highlighting not only our technological leadership but also our commitment to the highest standards of clinical validation,” said Hans Gangeskar, CEO of Overture Life.

“DaVitri has already shown potential to significantly increase clinical throughput while ensuring reproducibility in critical freezing and warming processes, allowing embryologists to prioritise personalised patient care. Our approach is rigorous and evidence-based because we understand how deeply personal this journey is for families.”

“Automation and standardisation in the embryology lab is an exciting step towards optimizing efficiency and efficacy in IVF. It allows us to deliver consistent and excellent care, while still giving us the flexibility to fine-tune protocols for our patients,” said Serena H. Chen, a reproductive endocrinologist at CCRM Fertility of NJ.

“We’re very excited about the potential to serve more patients by increasing lab capacity without sacrificing quality.”

This strategic round, supported by Overwater Ventures, GV (formerly Google Ventures), and Khosla Ventures, reflects a deep conviction in Overture’s science-led mission: to expand fertility access by making IVF labs more reproducible, efficient, and ultimately less cost-intensive.

“Fertility intersects healthcare, economics, and the most personal of human wishes,” said Kristina Simmons, Founder and managing partner at Overwater Ventures.

“Women have long faced irreversible biological timelines, and by making egg freezing cheaper, easier, and more clinically effective and predictable, it allows women and families to regain choice and opportunity. Overture’s platform provides a precise alternative that can run more cycles successfully, enabling women to freeze their eggs or pursue IVF on their own terms and timelines.

“By fitting the embryology protocols into a compact, desk-sized system, Overture is reinventing egg freezing and IVF for a better patient experience and strong, clinically reproducible outcomes with proven science.”